Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aequorin is a bioluminescent photoprotein originally isolated from the jellyfish *Aequorea victoria*. It consists of a 21–22 kDa protein (apoaequorin) bound to the prosthetic group coelenterazine and contains three EF-hand calcium-binding motifs[3][4][8]. Upon binding three calcium ions, aequorin undergoes oxidation of coelenterazine to generate blue light, which is measured as an indicator of intracellular calcium concentration changes[3][8]. Aequorin is widely used as a highly sensitive, non-invasive reporter of intracellular calcium dynamics in living cells and organisms across diverse systems (plants, fungi, animals)[3][5][7]. It acts as an *orthogonal* (non-interfering with host cell pathways) calcium sensor, as it does not bind mammalian calcium signaling components[1]. Fusion reporters combining aequorin with fluorescent proteins (e.g., GFP–aequorin) produce sensors with dual bioluminescence/fluorescence properties to enhance calcium detection[1][2]. Because it is not a human protein or disease-related target, and is instead a reporter tool, it is inappropriate to designate it as a canonical therapeutic target, receptor, or drug interaction site.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aequorin.